You are here: Home » Reuters » News
Business Standard

Sun Pharma tumbles after report of probe

Reuters 

(Reuters) - Shares of India's sank more than 10 percent on Monday after a report of a regulatory probe against the country's biggest by market value.

Markets regulator (SEBI) is likely to reopen an insider trading case against Sun, a report by the PTI carried https://economictimes.indiatimes.com/markets/stocks/news/sebi-may-reopen-insider-trading-case-against-sun-pharma/articleshow/66887801.cms in Indian daily Economic Times said.

The SEBI will also probe alleged lapses by some of Sun's promoters in raising funds overseas, the report added.

A whistleblower approached the SEBI with a document alleging various irregularities by the Mumbai-headquartered company, its promoter Dilip Shanghvi and others, the report said.

Sun Pharma, its and nine other entities had settled an insider trading probe last year after paying a settlement amount but the SEBI had not disclosed any details of the case at the time, the report added.

Sun did not immediately respond to a request from for comment.

Its shares hit their lowest in six months and were on course for their worst one-day performance in 18 months, weighing on the NSE index.

More than 37 million shares changed hands by 0647 GMT, over five times Sun's 30-day moving average trading volume.

The stock has already fallen over 16 percent since mid-November, when the drugmaker reported a surprise loss for the September quarter.

In the days following its financial results a brokerage raised concerns over corporate governance practices at the company, according to Sun responded last week, saying any issues only concerned historic events.

(Reporting by in Bengaluru; Editing by Sai Sachin Ravikumar)

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, December 03 2018. 12:25 IST
RECOMMENDED FOR YOU